Published in

Cambridge University Press, Antimicrobial Stewardship and Healthcare Epidemiology, 1(2), 2022

DOI: 10.1017/ash.2022.298

Links

Tools

Export citation

Search in Google Scholar

Estimating severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroprevalence from residual clinical blood samples, January–March 2021

Journal article published in 2022 by Daniel S. Graciaa ORCID, Hans P. Verkerke, Jeannette Guarner, Ana Maria Moldoveanu, Narayanaiah Cheedarla ORCID, Connie M. Arthur, Cheryl L. Maier ORCID, Andrew Neish, Sara C. Auld, Angie Campbell ORCID, Neel R. Gandhi ORCID, John D. Roback ORCID, N. Sarita Shah ORCID
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Abstract We describe severe acute respiratory coronavirus virus 2 (SARS-CoV-2) IgG seroprevalence and antigenemia among patients at a medical center in January–March 2021 using residual clinical blood samples. The overall seroprevalences were 17% by infection and 16% by vaccination. Spent or residual samples are a feasible alternative for rapidly estimating seroprevalence or monitoring trends in infection and vaccination.